Claas H Hinze
Overview
Explore the profile of Claas H Hinze including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hinze C, Foell D, Kessel C
Nat Rev Rheumatol
. 2023 Nov;
19(12):778-789.
PMID: 37923864
Systemic juvenile idiopathic arthritis (sJIA) is an inflammatory disease with hallmarks of severe systemic inflammation, which can be accompanied by arthritis. Contemporary scientific insights set this paediatric disorder on a...
2.
Weiden C, Saers M, Schwarz T, Hinze T, Wittkowski H, Kessel C, et al.
ACR Open Rheumatol
. 2023 Oct;
5(12):652-662.
PMID: 37786243
Objective: Rheumatic diseases are characterized by different patterns of immune overactivation. This study investigated the correlation of whole blood type 1 interferon (IFN) stimulated gene (ISG), IL18, and CXCL9 expression...
3.
Ganeva M, Fuehner S, Kessel C, Klotsche J, Niewerth M, Minden K, et al.
Pediatr Rheumatol Online J
. 2021 May;
19(1):64.
PMID: 33933108
Objective: Juvenile idiopathic arthritis (JIA) is a heterogeneous group of inflammatory joint disorders with a chronic-remitting disease course. Treat-to-target approaches have been proposed but monitoring disease activity and predicting the...
4.
Hinze T, Kessel C, Hinze C, Seibert J, Gram H, Foell D
Rheumatology (Oxford)
. 2021 Feb;
60(11):5165-5174.
PMID: 33576397
Objectives: The monoclonal IL-1β antibody canakinumab is approved for the treatment of systemic juvenile idiopathic arthritis (SJIA). Its efficacy has been proven in several trials, but not all patients show...
5.
Hinze C, Foell D
Arthritis Rheumatol
. 2019 Jun;
71(11):1969-1970.
PMID: 31233293
No abstract available.
6.
Hinze C, Foell D, Johnson A, Spalding S, Gottlieb B, Morris P, et al.
Arthritis Rheumatol
. 2018 Sep;
71(3):451-459.
PMID: 30225949
Objective: To determine the relationship between serum levels of S100A8/A9 and S100A12 and the maintenance of clinically inactive disease during anti-tumor necrosis factor (anti-TNF) therapy and the occurrence of disease...
7.
van de Geer A, Nieto-Patlan A, Kuhns D, Tool A, Arias A, Bouaziz M, et al.
J Clin Invest
. 2018 Jul;
128(9):3957-3975.
PMID: 29969437
Biallelic loss-of-function (LOF) mutations of the NCF4 gene, encoding the p40phox subunit of the phagocyte NADPH oxidase, have been described in only 1 patient. We report on 24 p40phox-deficient patients...
8.
Hinze C, Oommen P, Dressler F, Urban A, Weller-Heinemann F, Speth F, et al.
Pediatr Rheumatol Online J
. 2018 Jun;
16(1):40.
PMID: 29940960
Background: Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy in childhood and a major cause of morbidity among children with pediatric rheumatic diseases. The management of JDM is very...
9.
Hinze C, Speth F, Oommen P, Haas J
Pediatr Rheumatol Online J
. 2018 Jun;
16(1):38.
PMID: 29925381
Background: Juvenile Dermatomyositis (JDM) is a rare pediatric autoimmune disease with broad variations of the individual course. Data on the optimal management are mostly lacking. Currently treatment decisions are often...
10.
Speth F, Hinze C, Andel S, Mertens T, Haas J
Pediatr Rheumatol Online J
. 2018 Mar;
16(1):15.
PMID: 29499726
Background: The goal of this study was to apply the varicella zoster virus (VZV) vaccine to patients with pediatric rheumatic diseases (PRD) at risk for severe chickenpox, without interrupting their...